Blau Farmacêutica Balance Sheet Health
Financial Health criteria checks 6/6
Blau Farmacêutica has a total shareholder equity of R$1.9B and total debt of R$205.9M, which brings its debt-to-equity ratio to 11%. Its total assets and total liabilities are R$2.5B and R$630.2M respectively. Blau Farmacêutica's EBIT is R$364.3M making its interest coverage ratio -9.7. It has cash and short-term investments of R$391.7M.
Key information
11.0%
Debt to equity ratio
R$205.93m
Debt
| Interest coverage ratio | -9.7x |
| Cash | R$391.74m |
| Equity | R$1.87b |
| Total liabilities | R$630.16m |
| Total assets | R$2.50b |
Recent financial health updates
No updates
Recent updates
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Financial Position Analysis
Short Term Liabilities: BLAU3's short term assets (R$1.4B) exceed its short term liabilities (R$343.3M).
Long Term Liabilities: BLAU3's short term assets (R$1.4B) exceed its long term liabilities (R$286.9M).
Debt to Equity History and Analysis
Debt Level: BLAU3 has more cash than its total debt.
Reducing Debt: BLAU3's debt to equity ratio has reduced from 154.4% to 11% over the past 5 years.
Debt Coverage: BLAU3's debt is well covered by operating cash flow (127.4%).
Interest Coverage: BLAU3 earns more interest than it pays, so coverage of interest payments is not a concern.